Page last updated: 2024-12-08
isobavachin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
isobavachin: RN given for (S)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 193679 |
| CHEMBL ID | 491534 |
| CHEBI ID | 186172 |
| MeSH ID | M0443033 |
Synonyms (15)
| Synonym |
|---|
| 31524-62-6 |
| isobavachin |
| CHEMBL491534 |
| (2s)-7-hydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one |
| CHEBI:186172 |
| S9256 |
| AC-35022 |
| HY-N0762 |
| HMS3886L20 |
| CCG-267745 |
| CS-0009788 |
| MS-24834 |
| 7-hydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-en-1-yl)-2,3-dihydro-4h-1-benzopyran-4-one |
| DTXSID20953509 |
| AKOS040757105 |
Research Excerpts
Overview
Isobavachin is a dietary flavanone with multiple biological activities.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Isobavachin is a dietary flavanone with multiple biological activities. " | ( An integrated in vitro/in silico approach to assess the anti-androgenic potency of isobavachin. Huang, S; Luo, H; Ren, L; Shao, C; Zhang, J; Zhao, J, 2023) | 2.58 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " The developed method was applied to evaluating the pharmacokinetic study of 13 bioactive compounds after oral administration of Psoraleae Fructus in rat of different genders." | ( Simultaneous characterization of multiple Psoraleae Fructus bioactive compounds in rat plasma by ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry for application in sex-related differences in pharmacokinetics. Cheng, LY; Song, L; Wu, YL; Yang, L; Yu, YL; Zhang, Y; Zhou, K; Zhou, ZX, 2020) | 0.56 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| flavanones | Members of the class of flavans with a 3,4-dihydro-2-aryl-2H-1-benzopyran-4-one skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (11)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID378957 | Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 500 molar ratio relative to TPA | 2006 | Journal of natural products, Jan, Volume: 69, Issue:1 | Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects. |
| AID1238084 | Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at IC50 by MTT assay | 2015 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16 | Chemical constituents isolated from the Mongolian medicinal plant Sophora alopecuroides L. and their inhibitory effects on LPS-induced nitric oxide production in RAW 264.7 macrophages. |
| AID422533 | Cytotoxicity against NHEM cells assessed as cell viability 24 hrs by WST-8 assay | 2009 | Journal of natural products, Jan, Volume: 72, Issue:1 | Melanin synthesis inhibitors from Lespedeza cyrtobotrya. |
| AID378959 | Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 10 molar ratio relative to TPA | 2006 | Journal of natural products, Jan, Volume: 69, Issue:1 | Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects. |
| AID378956 | Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 1000 molar ratio relative to TPA | 2006 | Journal of natural products, Jan, Volume: 69, Issue:1 | Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects. |
| AID378961 | Inhibition of TPA-induced EBV-early antigen activation in human Raji cells | 2006 | Journal of natural products, Jan, Volume: 69, Issue:1 | Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects. |
| AID1238082 | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production after 24 hrs by Griess method | 2015 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16 | Chemical constituents isolated from the Mongolian medicinal plant Sophora alopecuroides L. and their inhibitory effects on LPS-induced nitric oxide production in RAW 264.7 macrophages. |
| AID422532 | Inhibition of melanin synthesis in NHEM after 24 hrs by liquid scintillation | 2009 | Journal of natural products, Jan, Volume: 72, Issue:1 | Melanin synthesis inhibitors from Lespedeza cyrtobotrya. |
| AID378962 | Scavenging activity against (+/-)-(E)-methyl-2-[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hexemide-induced NO generation in human Chang liver cells | 2006 | Journal of natural products, Jan, Volume: 69, Issue:1 | Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects. |
| AID378960 | Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio | 2006 | Journal of natural products, Jan, Volume: 69, Issue:1 | Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects. |
| AID378958 | Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 100 molar ratio relative to TPA | 2006 | Journal of natural products, Jan, Volume: 69, Issue:1 | Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 5 (41.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 19.87
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.87) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||